Correlation Between Allarity Therapeutics and GT Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Allarity Therapeutics and GT Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Allarity Therapeutics and GT Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Allarity Therapeutics and GT Biopharma, you can compare the effects of market volatilities on Allarity Therapeutics and GT Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Allarity Therapeutics with a short position of GT Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Allarity Therapeutics and GT Biopharma.

Diversification Opportunities for Allarity Therapeutics and GT Biopharma

-0.56
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Allarity and GTBP is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Allarity Therapeutics and GT Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GT Biopharma and Allarity Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Allarity Therapeutics are associated (or correlated) with GT Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GT Biopharma has no effect on the direction of Allarity Therapeutics i.e., Allarity Therapeutics and GT Biopharma go up and down completely randomly.

Pair Corralation between Allarity Therapeutics and GT Biopharma

Given the investment horizon of 90 days Allarity Therapeutics is expected to under-perform the GT Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Allarity Therapeutics is 1.48 times less risky than GT Biopharma. The stock trades about -0.29 of its potential returns per unit of risk. The GT Biopharma is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  850.00  in GT Biopharma on September 12, 2024 and sell it today you would lose (546.00) from holding GT Biopharma or give up 64.24% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Allarity Therapeutics  vs.  GT Biopharma

 Performance 
       Timeline  
Allarity Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
GT Biopharma 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in GT Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, GT Biopharma reported solid returns over the last few months and may actually be approaching a breakup point.

Allarity Therapeutics and GT Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Allarity Therapeutics and GT Biopharma

The main advantage of trading using opposite Allarity Therapeutics and GT Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Allarity Therapeutics position performs unexpectedly, GT Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will offset losses from the drop in GT Biopharma's long position.
The idea behind Allarity Therapeutics and GT Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins